Ablynx 2011 annual results (Ablynx) - Feb 23, 2012 - P2 POC data anticipated in H2 2012
Anticipated P2 data • Immunology • Rheumatoid Arthritis
|
|
Anti-IL-6R - summary
Positive data from SAD part of Phase I/II study
Started MAD part of Phase I/II study in November 2011 (3 dose groups, with dosing interval every 4 weeks or 8 weeks)
Phase II POC data expected in H2 2012
In RA alone, the market share of biological non-TNFα blockers is expected to grow from 15% in 2009 to 35% in 2019, with total expected sales of $4.2bn in 2019
|